Relay Therapeutics Reports Strong Phase 2 Data for Zovegalisib in Vascular Anomalies, Demonstrating High Response Rates and Favorable Safety

summarizeSummary

Relay Therapeutics reported strong initial Phase 2 clinical data for zovegalisib in vascular anomalies, showing high volumetric response rates and significant symptomatic improvement with a favorable safety profile.

check_boxKey Events · Product Development and Regulatory · RLAY

• Positive Phase 2 Efficacy Data

  Zovegalisib achieved a 65% volumetric response rate (VRR) across doses in 20 response-evaluable patients with PIK3CA-driven vascular anomalies. 95% of patients experienced lesion reduction.

• Significant Symptomatic Improvement

  Clinical outcome assessments showed 89% of patients experienced investigator-reported clinical improvement (IGIC) and 79% patient-reported improvement (PGIC) at week 12.

• Favorable Safety and Tolerability

  The safety profile was generally as expected, with low-grade, manageable, and reversible treatment-related adverse events (TRAEs) at 100mg and 300mg BID. No patients discontinued treatment due to adverse events.

• Clear Development Path Forward

  Expansion cohorts for adults and adolescents have been opened at 400mg once daily (QD) and 300mg BID, with pediatric dose-finding ongoing, supporting a potential accelerated approval pathway.

auto_awesomeAnalysis · RLAY · Life Sciences

Relay Therapeutics announced compelling initial Phase 2 clinical data for zovegalisib in PIK3CA-driven vascular anomalies. The drug achieved a 65% volumetric response rate and significant symptomatic improvement in a patient population with limited treatment options. The favorable safety profile, particularly at lower doses, suggests potential for chronic use and a differentiated profile compared to existing therapies. This positive data significantly de-risks the program and supports a clear path towards potential accelerated approval, expanding the commercial opportunity for zovegalisib beyond its breast cancer indications.